Madrigal Pharmaceuticals Inc (MDGL)

$514.39 -22.56 (-4.20%)
Market Cap 12.16B
Revenue (ttm) 958.40M
Net Income (ttm) -288.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.08%
Debt to Equity Ratio 0.63
Volume 303,700
Avg Vol 334,372
Day's Range N/A - N/A
Shares Out 23.06M
Stochastic %K 85%
Beta -1.07
Analysts Strong Sell
Price Target $664.00

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 267 824 2827
Address:
Four Tower Bridge, 200 Barr Harbor Drive Suite 200, West Conshohocken, United States
Wallst45
Wallst45 Jul. 1 at 6:54 PM
$MDGL what a low volume manipulation as usual lol 😂
1 · Reply
Layne_Thomas_Staley
Layne_Thomas_Staley Jun. 30 at 10:45 PM
$GANX Look at $MDGL chart for what a successful first mover brought to market looks like for a previously untreated medical epidemic. I think Gain will be acquired, but in biotech, first mover advantage is everything. Ultimately, the science here is bulletproof and the need is dire.
2 · Reply
Live2ride
Live2ride Jun. 30 at 7:40 PM
$MDGL Back to the top of the box. Looking for that breakout.
0 · Reply
CDMO
CDMO Jun. 30 at 7:34 PM
$MDGL solid
0 · Reply
Live2ride
Live2ride Jun. 30 at 7:30 PM
$MDGL It's getting ready!!
0 · Reply
Wallst45
Wallst45 Jun. 30 at 7:10 PM
$MDGL very undervalued
0 · Reply
revuelto
revuelto Jun. 30 at 6:13 PM
$MDGL deep bargain 🥳 🎉
0 · Reply
Wallst45
Wallst45 Jun. 30 at 5:11 PM
$MDGL I bet 600
0 · Reply
Live2ride
Live2ride Jun. 30 at 3:36 PM
$MDGL Liking the setup. Need to hold 535 area, then break 547/550 and watch the real run begin when shorts cover. I did lighten up some swing shares today at 539. Good luck longs.
0 · Reply
Wallst45
Wallst45 Jun. 30 at 3:09 PM
$MDGL Squeeze
0 · Reply
Latest News on MDGL
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Jul 1, 2026, 9:19 PM EDT - 6 minutes ago

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Jun 22, 2026, 4:05 PM EDT - 9 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals management to meet with Piper Sandler

2026-06-17T20:21:37.000Z - 14 days ago

Madrigal Pharmaceuticals management to meet with Piper Sandler

Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

2026-06-11T10:41:26.000Z - 20 days ago

Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 11:20 AM EDT - 21 days ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

2026-05-27T14:23:26.000Z - 5 weeks ago

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

May 20, 2026, 8:00 AM EDT - 6 weeks ago

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

2026-05-13T13:52:07.000Z - 7 weeks ago

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

2026-05-07T16:42:06.000Z - 7 weeks ago

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

2026-05-07T13:49:17.000Z - 7 weeks ago

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

2026-05-07T07:31:11.000Z - 7 weeks ago

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

2026-05-07T00:53:12.000Z - 2 months ago

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

Madrigal Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Earnings release: Q1 2026

Madrigal Pharmaceuticals Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Slides: Q1 2026

Madrigal Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Quarterly report: Q1 2026

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

May 6, 2026, 7:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

2026-05-05T12:17:38.000Z - 2 months ago

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

ARWR

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

May 5, 2026, 8:00 AM EDT - 2 months ago

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 5, 2026, 8:00 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

ARWR

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading

2026-03-26T19:00:15.000Z - 3 months ago

Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 2:30 PM EST - 4 months ago

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA

2026-02-20T12:26:01.000Z - 4 months ago

Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Madrigal Pharmaceuticals Annual report: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Annual report: Q4 2025

Madrigal Pharmaceuticals Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Earnings release: Q4 2025

Madrigal Pharmaceuticals Slides: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Slides: Q4 2025

Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)

2026-02-19T12:08:24.000Z - 4 months ago

Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Feb 11, 2026, 6:25 AM EST - 5 months ago

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo

2026-02-11T10:10:18.000Z - 5 months ago

Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Feb 11, 2026, 5:00 AM EST - 5 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA

2026-02-03T11:50:48.000Z - 5 months ago

Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Feb 2, 2026, 8:05 AM EST - 5 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

2026-01-27T21:31:28.000Z - 5 months ago

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Jan 21, 2026, 4:05 PM EST - 5 months ago

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens

2026-01-20T10:55:09.000Z - 5 months ago

Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 6 months ago

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 6 months ago

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen

2026-01-12T13:47:51.000Z - 6 months ago

Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen

PFE

Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

2026-01-09T13:10:25.000Z - 6 months ago

Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

PFE

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Jan 9, 2026, 8:00 AM EST - 6 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:05 PM EST - 7 months ago

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 1:30 PM EST - 7 months ago

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 4:15 PM EST - 7 months ago

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 3:30 AM EST - 7 months ago

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Nov 17, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Nov 10, 2025, 8:00 AM EST - 8 months ago

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Madrigal Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Earnings release: Q3 2025

Madrigal Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Slides: Q3 2025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Nov 4, 2025, 7:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 8 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MEDI

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Madrigal Pharma CEO talks competition in the liver disease treatment space

Oct 16, 2025, 6:18 PM EDT - 9 months ago

Madrigal Pharma CEO talks competition in the liver disease treatment space

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:45 AM EDT - 10 months ago

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Aug 19, 2025, 4:05 PM EDT - 11 months ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 10:30 AM EDT - 11 months ago

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Aug 8, 2025, 6:15 PM EDT - 11 months ago

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Madrigal Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Earnings release: Q2 2025

Madrigal Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Slides: Q2 2025

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Jul 30, 2025, 5:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 7:35 AM EDT - 1 year ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 20, 2025, 6:30 AM EDT - 1 year ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Madrigal Pharmaceuticals Transcript: Status Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Status Update

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 10, 2025, 7:15 AM EDT - 1 year ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

Madrigal Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Quarterly report: Q1 2025

Madrigal Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q1 2025

Madrigal Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Slides: Q1 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:10 AM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 6:33 PM EST - 1 year ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Madrigal Pharmaceuticals Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Annual report: Q4 2024

Madrigal Pharmaceuticals Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q4 2024

Madrigal Pharmaceuticals Slides: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Slides: Q4 2024

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 7:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 21, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Feb 12, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Madrigal Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Madrigal Pharmaceuticals Slides: FY 2025

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 13, 2025, 6:45 AM EST - 1 year ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 1 year ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Wallst45
Wallst45 Jul. 1 at 6:54 PM
$MDGL what a low volume manipulation as usual lol 😂
1 · Reply
Layne_Thomas_Staley
Layne_Thomas_Staley Jun. 30 at 10:45 PM
$GANX Look at $MDGL chart for what a successful first mover brought to market looks like for a previously untreated medical epidemic. I think Gain will be acquired, but in biotech, first mover advantage is everything. Ultimately, the science here is bulletproof and the need is dire.
2 · Reply
Live2ride
Live2ride Jun. 30 at 7:40 PM
$MDGL Back to the top of the box. Looking for that breakout.
0 · Reply
CDMO
CDMO Jun. 30 at 7:34 PM
$MDGL solid
0 · Reply
Live2ride
Live2ride Jun. 30 at 7:30 PM
$MDGL It's getting ready!!
0 · Reply
Wallst45
Wallst45 Jun. 30 at 7:10 PM
$MDGL very undervalued
0 · Reply
revuelto
revuelto Jun. 30 at 6:13 PM
$MDGL deep bargain 🥳 🎉
0 · Reply
Wallst45
Wallst45 Jun. 30 at 5:11 PM
$MDGL I bet 600
0 · Reply
Live2ride
Live2ride Jun. 30 at 3:36 PM
$MDGL Liking the setup. Need to hold 535 area, then break 547/550 and watch the real run begin when shorts cover. I did lighten up some swing shares today at 539. Good luck longs.
0 · Reply
Wallst45
Wallst45 Jun. 30 at 3:09 PM
$MDGL Squeeze
0 · Reply
Cap_00
Cap_00 Jun. 30 at 2:49 PM
$MDGL GlP-1 don't work inside the liver. GLP-1s are used for weight loss and once achieved, they usually stop 1-2 years and weight usually comes back. Liver improvements are then also temporary. GLP-1s will be used along with Rezdiffra. This is why they want to combine GLP-1 and Rez in one pill. If F4c data is positive, this company is on its way to becoming a 50B company.
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jun. 30 at 4:12 AM
$GALT $MDGL In regards to not taking the time to set up an exhibition table that was provided free of charge
0 · Reply
Wallst45
Wallst45 Jun. 29 at 7:47 PM
$MDGL very strong volumes into close. What’s up ??
1 · Reply
Wallst45
Wallst45 Jun. 29 at 7:14 PM
$MDGL very undervalued, just getting ready to blast out
0 · Reply
Curiousoso
Curiousoso Jun. 29 at 6:32 PM
$MDGL Just flagging for greatness. Thumb twiddlin' time.
0 · Reply
Quantumup
Quantumup Jun. 29 at 1:57 PM
Piper Sandler reiterated $MDGL Overweight-$900 and said, Recently, we hosted MDGL for an investor dinner and conducted a MASH KOL call, where there was significant interest in MAESTRO-NASH-OUTCOMES with expected completion 2027. $IVA $NVO ALGS VKTX Here's what elsePiper Sandler had to say: https://x.com/Quantumup1/status/2071593598055854370?s=20
0 · Reply
1986iamwallstreet
1986iamwallstreet Jun. 29 at 1:45 PM
$MDGL undervalued
0 · Reply
JoeB07
JoeB07 Jun. 29 at 3:12 AM
$MDGL bottom trendline(s) holding...
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jun. 28 at 11:20 PM
$MDGL appreciate the ice cream recipe bet it goes great with our brownies.
0 · Reply
Live2ride
Live2ride Jun. 28 at 12:13 AM
$MDGL Anxious to see if we bounce back on Monday from the wall st games played the last few minutes of trading.
0 · Reply
Wallst45
Wallst45 Jun. 26 at 8:23 PM
$MDGL Madirgal is NOT part of any index reconstitution. Check list below 👇🏼 https://www.lseg.com/en/ftse-russell/russell-reconstitution
0 · Reply
Cap_00
Cap_00 Jun. 26 at 8:04 PM
$MDGL 2026 Russell 2000 reconstitution
1 · Reply